SCHEMBL2835895

SCHEMBL2835895

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COc2cccc(-c3ccccc3)c2)[C@@H](O)[C@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.65
ADORA1 P30542 5/20 0.65
DNPH1 O43598 2/20 0.62
P2RY1 P47900 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
P2RY2 P41231 3/20 0.60
ADORA3 P0DMS8 2/20 0.60
ADORA2A P29274 2/20 0.60
ADORA2B P29275 2/20 0.60
SRC P12931 2/20 0.60
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
MAPK1 P28482 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835899 1.00 METTL3 (0.65) METTL3ADORA1DNPH1P2RY1SMN1; SMN2
SCHEMBL1434032 0.91 ADORA1 (0.72) METTL3ADORA1DNPH1P2RY1SMN1; SMN2
SCHEMBL6905464 0.91 ADORA1 (0.72) METTL3ADORA1DNPH1P2RY1SMN1; SMN2
SCHEMBL2835155 0.85 ADORA1 (0.67) ADORA1DNPH1P2RY1SMN1; SMN2P2RY2
SCHEMBL2835149 0.85 ADORA1 (0.67) ADORA1DNPH1P2RY1SMN1; SMN2P2RY2
SCHEMBL22458248 0.83 ADORA1 (0.65) ADORA1DNPH1P2RY1SMN1; SMN2P2RY2
SCHEMBL6902192 0.83 ADORA1 (0.62) METTL3ADORA1DNPH1P2RY1SMN1; SMN2
SCHEMBL8744184 0.82 ADORA1 (0.66) ADORA1DNPH1P2RY1SMN1; SMN2P2RY2
SCHEMBL10997946 0.82 ADORA1 (0.76) ADORA1DNPH1P2RY1SMN1; SMN2P2RY2
SCHEMBL6907702 0.82 METTL3 (0.70) METTL3ADORA1DNPH1P2RY1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160351-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS NUON THERAPEUTICS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160351-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS XDH, SLC10A1, SLC10A6 METTL3 2014/4885ADORA1 136/4885DNPH1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.